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Factors Influencing the Relationship Between the Dose of Amlodipine
Required for Blood Pressure Control and Change in Blood Pressure
in Hypertensive Cats
E.S. Bijsmans, M. Doig, R.E. Jepson, H.M. Syme, J. Elliott, and L. Pelligand
Background: Hypertension is a common problem in elderly cats. In most cats, systolic blood pressure (SBP) of
<160 mmHg is achieved in response to amlodipine besylate at either 0.625 or 1.25 mg q24h. The individual cat factors
determining dose requirement dose have not been explored.
Aims: To determine whether individual cat factors influence the dose of amlodipine required to achieve adequate blood
pressure control and to determine whether factors other than the prescribed dose of drug alter the achieved plasma amlodipine
concentrations.
Methods: Fifty-nine hypertensive cats that required 0.625 mg (A) and 41 cats that required 1.25 mg (B) amlodipine to
reach a target SBP of <160 mmHg were identified, and plasma amlodipine concentrations were determined. Comparisons
were made between groups, and multivariable linear regression models were performed to investigate predictors of antihyper-
tensive response.
Results: Cats that required a greater dose of amlodipine had significantly higher SBP at diagnosis of hypertension
(A: (median [25th, 75th percentile]) 182 [175,192] mmHg; B: 207 [194,217] mmHg, P < .001), but comparable blood pressure
was achieved after treatment. Plasma amlodipine concentrations were directly related to the dose of amlodipine administered.
At diagnosis, cats in group B had significantly lower plasma potassium concentration (A: 4.1 [3.8,4.5]; B: 3.8 [3.6,4.2] mEq/L,
P < .01). Weight did not differ between groups. The decrease in SBP was directly and independently associated with the SBP
at diagnosis and the plasma amlodipine concentration.
Conclusions and Clinical Importance: Cats with higher blood pressure at diagnosis might require a greater dose of
amlodipine to control their blood pressure adequately. Differences in amlodipine pharmacokinetics between cats do not seem
to play a role in the antihypertensive response.
Key words: Chronic kidney disease; Feline; Hypertension.
Systolic hypertension is a common problem in theelderly cat population, particularly in cats with
chronic kidney disease (CKD).1 Left untreated, it can
have detrimental effects and lead to damage to organs
with a rich arterial and arteriolar supply, such as the
eye, kidney, and brain, often referred to as target organ
damage (TOD).1 The goal of antihypertensive treatment
is to effectively decrease the risk of TOD.1 In human
medicine, more aggressive treatment is recommended
for patients with more severe hypertension.2
Amlodipine besylate is currently regarded as the first-
choice antihypertensive treatment in cats.1 The first
reports on the use of amlodipine besylate for treatment
of hypertension in cats were published in 1994,3,4 and
since then, two placebo-controlled clinical trials have
been published.5,6 Amlodipine is a second-generation
dihydropyridine and exerts its effects by blocking L-type
calcium channels in vascular smooth muscle. It binds
and dissociates from its receptor fairly slowly, which
accounts for the gradual onset and slow waning of
effect.7 This, in combination with its long plasma half-
life, means amlodipine only needs to be administered
once every 24 hours.8 The currently recommended dose
for cats is 0.125–0.5 mg/kg, with regular blood pressure
checks and potential dose adjustment to achieve ade-
quate blood pressure control.1 It has been suggested
that heavier cats need a higher dose of amlodipine.5,9,10
The pathogenesis of hypertension in cats is still
poorly understood. Cats with CKD are at greater risk
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of developing hypertension, and plasma creatinine con-
centration is an independent risk factor for the develop-
ment of hypertension.11 Hypertensive cats have lower
plasma potassium concentrations than their normoten-
sive counterparts.12 However, investigations into the
activation of the renin–angiotensin–aldosterone system
(RAAS) have reported heterogeneous results.13 As
amlodipine is thought to produce its antihypertensive
effects by reducing peripheral resistance, investigations
into the factors influencing response to amlodipine
could help elucidate the pathophysiologic mechanisms
driving hypertension in cats with and without CKD.
The aim of this study was to determine the factors
influencing the dose of amlodipine required to achieve
adequate control of blood pressure in hypertensive cats.
We hypothesized that measurement of plasma amlodip-
ine concentration at the point of blood pressure control
would help to identify whether individual pharmacoki-
netics play a role in this. To improve optimization of
antihypertensive therapy, comparisons were made between
the low-dose and high-dose group, and clinical and labo-
ratory variables were investigated as possible predictors of
blood pressure response.
Materials and Methods
Clinics and Case Selection
A population of cats that had undergone diagnosis and therapy
for systemic hypertension at two first opinion practices (People’s
Dispensary for Sick Animals in Bow and Beaumont Sainsbury
Animal Hospital in Camden) between January 2001 and December
2013 was identified. These cats had all been invited to the clinic as
part of a screening program of elderly cats (≥9 years of age), or
because they were suspected to suffer from diseases that were of
interest to the veterinary researchers working in the practice
(hypertension, CKD, hyperthyroidism, or a combination thereof).
Each of these cats had undergone a standardized visit protocol,
which included a full history and a physical examination, including
blood pressure measurement and blood and urine sampling. A
noninvasive Doppler techniquea was used to measure systolic
blood pressure (SBP) after a period of acclimatization. Average
SBP was calculated from 5 consecutive readings after discarding
the first reading. If average SBP was ≥160 mmHg, indirect fun-
doscopy was performed after applying one drop of tropicamide
1% to both eyes.
At first visit to the clinic, informed owner consent was
obtained to collect blood samples via jugular venipuncture and
urine samples by cystocentesis. The standard clinic protocols,
information sheets, and consent forms for use of residual samples
for research were approved by the Royal Veterinary College’s
Ethics and Welfare Committee (URN: 2013 1258). Blood samples
were collected into lithium heparin and EDTA tubes and held on
ice for a maximum of 6 hours before centrifugationb and separa-
tion. Plasma biochemistry was performed at an external labora-
tory,c and residual sample was stored at 80°C until further
analysis. Plasma total T4 concentration was measured in all cats
within 6 months of inclusion in the study. All cats diagnosed
with hyperthyroidism (total T4 >40 nmol/L with canine thyroid
stimulating hormone [TSH] <0.03 ng/mL, or a total T4
>55 nmol/L) were excluded from the study, unless a successful
thyroidectomy (confirmed by total T4 measurement) had been
performed ≥90 days before inclusion, to allow stabilization of
glomerular filtration rate.14 Urine samples were collected by
cystocentesis if possible, and urine dipstick evaluation was per-
formed and urine specific gravity (USG) was measured by refrac-
tometry. In addition, microscopic sediment examination was
undertaken and, if bacteriuria or pyuria was found, bacterial cul-
ture and sensitivity testing was performed. Cats that were being
administered Angiotensin Converting Enzyme (ACE) inhibitors
or other blood pressure altering medications were excluded.
Systemic hypertension was diagnosed when cats had a SBP
≥170 mmHg on two consecutive visits (reliably placing them in the
category that is at moderate risk of developing TOD)1 or SBP
≥160 mmHg with concurrent evidence of hypertensive retinopathy
on indirect fundoscopy. CKD was diagnosed in cats with renal
azotemia (plasma creatinine concentration ≥2.0 mg/dL either on
two consecutive visits >2 weeks apart or in conjunction with USG
<1.035).
Treatment Protocol
All cats were started on 0.625 mg amlodipine besylate (1/8
tablet of a 5-mg human formulationd) once daily and invited
back for a blood pressure recheck 1–2 weeks later. Target SBP
was defined as <160 mmHg and the amlodipine dose was dou-
bled if SBP was ≥160 mmHg on follow-up visits, to a maximum
of 2.5 mg amlodipine per day. After adequate antihypertensive
control was achieved, a blood sample was obtained to assess any
potential changes in kidney function with antihypertensive treat-
ment, and owners were invited back to the clinic every 8 weeks,
with blood and urine samples taken every 16 weeks. An over-
view of this protocol can be found in Figure 1. The samples that
were used for amlodipine measurement in this study were all
taken at the first visit that blood pressure was considered ade-
quately controlled (SBP <160 mmHg), and only cats that
achieved control on 0.625 and 1.25 mg were included. No
attempt was made to obtain blood samples at any particular
time of day, although all cats were seen and sampled between
9 AM and 1 PM. Owners were instructed to medicate their cat
at the same time point every day, but were free to decide at
which time this would be.
Measurement Method
Plasma amlodipine concentration was determined using
high-performance liquid chromatography with tandem mass spec-
trometric detection (LC/MS/MS). Samples of cats not on amlodip-
ine, and cats that were on amoxicillin/clavulanic acid antibiotic
therapy, methimazole, and meloxicam were used as controls.
Amlodipine was quantified in EDTA feline plasma using amlodip-
ine-d4 as the internal standard over the concentration range of
1–500 ng/mL. Amlodipine was extracted from 50 lL plasma
samples by protein precipitation using 200 lL of acetonitrile. The
proteins were removed by centrifugation, and the acetonitrile was
transferred to another 96-well plate prior to injection on to a
Thermo Accucore RP-MS 2.6 lm 80A (2.1 9 50 mm) solid core
HPLC column using a CTC autosampler connected to a Jasco XLC
UPLC system (Jasco Corporation, HACHIOJI-SHI, TOKYO,
Japan). The analytes were chromatographed using a 0.1% (v/v) for-
mic acid acetonitrile gradient flowing at 0.6 mL/min. Amlodipine
was quantified by multiple reaction monitoring (MRM) using posi-
tive-ion atmospheric pressure ionization on an ABSciex (Concord,
Ontario, Canada) API4000 tandem mass spectrometer. The MRM
transitions used were m/z 409.2 ? 238.0 and 413.2 ? 238.0 for
amlodipine and amlodipine-d4, respectively. Calibration curves were
fitted using a quadratic regression weighted 1/x2. Accuracy and
precision of the method were evaluated at 3, 30 and 400 ng/mL.
Intrabatch accuracy ranged from 92.0 to 111.7%. Interbatch accu-
racy ranged between 95.5 and 107.5%. Imprecision was <6.5%.
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Statistical Analyses
Statistical analyses of the data were performed using R 3.1.1e
and GraphPad Prism 6f . To investigate differences in clinical pre-
sentation, comparisons were made between clinical and biochemi-
cal variables of cats that were controlled on 0.625 mg/day (A) and
cats that needed a dose increase to 1.25 mg/day (B). Comparisons
were made between groups A and B at initial visit using a Stu-
dent’s t-test or Mann–Whitney U-test where appropriate, and
results are described as mean  SD or median ([25th, 75th
percentile]). Cross-sectional comparisons for plasma amlodipine
concentrations at first controlled visit were made using a Mann–
Whitney U-test. Proportion of cats diagnosed with CKD,
proportion of cats in International Renal Interest Society (IRIS)
stage 2, and proportion of hypokalemic cats were compared
between groups using a Fisher’s exact test. Significance was set at
P < .05.
The absolute change in SBP was calculated as the average SBP
at diagnosis (averaging the SBP at hypertensive visits) minus the
SBP at first controlled visit. Univariable linear regression models
were performed with absolute change in SBP in response to
amlodipine treatment as the dependent variable and plasma
amlodipine concentration, dose in mg/kg, time on treatment in
days, weight, age, heart rate, SBP at hypertensive visit, packed cell
volume (PCV), plasma creatinine and urea concentration, plasma
potassium, sodium, chloride, total calcium, and cholesterol concen-
tration as explanatory variables. Variables were log transformed if
necessary to meet normality criteria, and variables significant at
the 10% level were included in the multivariable linear regression
model without model selection.
Results
Clinical Data
An overview of the clinical and biochemical variables
can be found in Table 1, and a schematic representation
of the treatment protocol and included subjects can be
found in Figure 1. A total of 100 cats (50 female [2 of
which were entire] and 50 male neutered) were identi-
fied. The majority of cats (73) were domestic short hair,
followed by Burmese (8) and domestic long hair (7). At
the first time point, SBP was considered effectively con-
trolled, 59 cats were on 0.625 mg/day, and 41 cats were
receiving 1.25 mg/day. At first controlled visit, cats that
had adequate antihypertensive response to 0.625 mg
had been receiving therapy for a median of 14 days,
whereas cats that required 1.25 mg had been on treat-
ment with a median of 28 days, which is concordant
with the clinic’s treatment protocol. The majority of
cats (71/100) had been diagnosed with CKD, and the
number of cats with CKD was not significantly different
between groups (P = .13), nor was the number of cats
in IRIS stage 2 (P = .30).
Cross Sectional Study
Systolic blood pressure at the hypertensive visit dif-
fered significantly between groups (A: 182 [175, 192]
mmHg; B: 207 [194, 217] mmHg, P < .001), but compa-
rable post-treatment SBP was achieved (A: 145.6 [134.0,
152.4] mmHg; B: 146.2 [136.2, 152.4] mmHg, P = .55),
as shown in Figure 2. Plasma amlodipine concentration
was approximately twice as high in cats on 1.25 mg
compared to those receiving 0.625 mg (B: 70.5 [48.8,
98.6] ng/mL versus A: 33.1 [24.9, 53.2] ng/mL,
P < .001), as was the dose in mg/kg that the cats were
receiving (B: 0.33  0.09 mg/kg, A: 0.17  0.04 mg/kg;
P < .001). No significant differences were found
between pretreatment values from groups A and B for
age, weight, PCV, plasma albumin, creatinine, urea,
phosphate, total calcium, sodium, chloride, and choles-
terol concentration, and USG. Group B had a signifi-
cantly lower plasma potassium concentration (mean
plasma potassium concentration was 0.3 mEq/L lower
Fig 1. Treatment protocol for the initial BP stabilisation and overview of the groups included in the study.
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in group B than in group A, P < .01; see also Table 1),
but the number of hypokalemic cases (reference range
potassium 3.50–5.50 mEq/L) did not significantly differ
between groups (P = .22).
Linear Regression
Plasma amlodipine concentration, dose in mg/kg, SBP
at hypertensive visit, and plasma potassium were all asso-
ciated with the absolute drop in SBP at the 10% level in
the univariable analyses (Table 2) and were included in
the multivariable model. Plasma amlodipine concentra-
tion and the SBP at hypertensive visit remained positively
and significantly associated with decrease in SBP in the
final model (P < .001).
Discussion
Human patients with severe elevations in blood pres-
sure are started on more aggressive antihypertensive
treatment (ie, higher doses of medication or multiple
medications that are being started at the same time)
than patients with moderate blood pressure increases.15
The aim of antihypertensive treatment is to achieve
effective control of SBP as quickly as possible while
eliciting few adverse effects, in order to decrease the
risk of (further) TOD. Predictors of the dose required
to achieve effective blood pressure control in an indi-
vidual patient could help in achieving this, and human
studies have made efforts to identify predictors of
response to several different classes of antihypertensive
medication.16–18
In the current study, cats with a higher SBP at pre-
sentation needed a higher dose of amlodipine to
decrease the SBP to acceptable levels. In addition, the
decrease in SBP associated with amlodipine treatment
was independently and positively associated with both
the pretreatment SBP and the plasma amlodipine con-
centration. Administration of a higher dose in mg/kg
was associated with proportionately higher plasma
amlodipine concentrations. This finding suggests that
individual cat variation in amlodipine pharmacokinetics
or owner compliance is unlikely to explain the dose
required to achieve effective blood pressure control with
amlodipine in the majority of cats. However, it is nota-
ble that only cats with acceptable control were included
in this study, and it cannot be ruled out that compli-
ance plays a role in cats that do not respond to higher
doses, such as cats that need a dose of 2.5 mg q24h, or
need additional medications such as benazepril. The
Table 1. Clinicopathologic variables for groups A and
B at initial visit.
Group A Group B
Dose of amlodipine
(mg/cat/24 hour)
0.625 1.25
N (CKD) 59 (45) 41 (26)
Age (years) 15.3 [13.7, 16.5] 15.0 [13.3, 16.1]
Weight (kg) 3.77 [3.16, 4.49] 3.86 [3.42, 4.40]
SBP (mmHg) 182 [175, 192] 207 [194, 217]
Heart rate (bpm) 187 [177, 215] 192 [180, 200]
PCV (%) 36 [31, 38] 36 [32, 39]
Albumin (g/dL) 3.1 [2.9, 3.3] 3.2 [3.1, 3.4]
Creatinine (mg/dL) 2.3 [1.8, 2.8] 2.3 [1.7, 2.7]
Urea (mmol/L) 16.0 [12.6, 21.6] 14.5 [10.7, 21.6]
Phosphate (mg/dL) 4.30 [3.39, 4.83] 4.15 [3.31, 5.27]
Total calcium (mg/dL) 10.04 [9.72, 10.52] 10.20 [9.76, 10.62]
Sodium (mEq/L) 153.0 [151.8, 154.6] 153.0 [151.5, 154.5]
Potassium (mEq/L) 4.1 [3.8, 4.5] 3.8 [3.6, 4.2]
Chloride (mEq/L) 116.8 [115.5, 119.6] 116.9 [115.1, 118.7]
Cholesterol (mg/dL) 200.8 [164.1, 254.8] 200.8 [172.8, 243.2]
USG 1.018 [1.016, 1.024] 1.020 [1.017, 1.022]
SBP, systolic blood pressure; PCV, packed cell volume; USG,
urine specific gravity; CKD, chronic kidney disease.
Variables shown in bold are significantly different between the
two groups (P < .05). All values are presented as median [25th,
75th percentile].
Hy
pe
rte
ns
ive
 vi
sit
Co
ntr
oll
ed
 vi
sit
0
100
120
160
200
SB
P 
(m
m
H
g)
240
0.625 mg
1.25 mg
Fig 2. Graphical presentation of the systolic blood pressure (SBP) at hypertensive visit and at first controlled visit for cats on 0.625 and
1.25 mg. Cats that required a dose of 1.25 mg to decrease their SBP to <160 mmHg had significantly higher blood pressure at diagnosis
(black line) than did cats that needed 0.625 mg, but comparable SBP after treatment.
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same direct correlation between plasma amlodipine con-
centration and decrease in blood pressure occurs in
humans and rats.8,19
The SBP before treatment was independently associ-
ated with the absolute decrease in blood pressure with
antihypertensive treatment. This could be explained by
the clinical protocols used. Whereas in human hyperten-
sive subjects, specific blood pressure goals have been
described for different clinical situations,2 the target for
all cats enrolled in the current study was SBP of
<160 mmHg. The greater decrease in blood pressure
could therefore be explained by having a higher blood
pressure at baseline. However, it is likely that more fac-
tors play a role. Studies of human patients have
described that blood pressure response to amlodipine is
greater with more severe hypertension.17 This could
indicate that in more severely hypertensive subjects,
increased peripheral resistance plays a greater role in
the pathophysiology of hypertension.17 Amlodipine low-
ers blood pressure by acting on the vascular smooth
muscle cells, and the direct correlation between drop in
blood pressure and plasma amlodipine concentration
might indicate that raised systemic vascular resistance is
(partly) responsible for the elevation in blood pressure
in cats.
Cats that needed a dose increase to 1.25 mg had sig-
nificantly lower plasma potassium concentration.
Plasma potassium concentration is regulated by the
RAAS and the kidneys, and there are multiple possible
explanations for the finding of lower plasma potassium
in less responsive cats. One explanation could be that
greater activation of the RAAS occurred in Group B
cats compared to Group A cats. Activation of the
RAAS is variable in hypertensive cats,13 and ACE inhi-
bitors show a relative lack of efficacy. This implies that
although possibly involved, renin-dependent mecha-
nisms are unlikely to be the main cause of hypertension
in feline patients. Other possible underlying causes of
hypertension that are associated with low plasma potas-
sium concentration should be explored in cats requiring
high doses of amlodipine to treat their hypertension,
one of which is nonrenin-dependent increases in plasma
aldosterone concentration. The reported incidence of
primary hyperaldosteronism is increasing in cats,20 pos-
sibly because of a greater awareness of the disease.
Aldosterone was not measured in cats in the current
study, and abdominal ultrasound examinations were
not routinely performed, and it is therefore unclear
whether this disease played a role. It should be noted
that the majority of the cats included in this study had
concurrent CKD. Hypokalemia is fairly common in cats
with CKD and could be due to decreased intake or
increased urinary loss of potassium.21 The hypertensive
cats included in this study had comparable renal func-
tion and the proportion of cats with CKD and cats
with IRIS CKD stage 2 was equal in both groups
(Table 1), suggesting that stage of CKD did not have
an influence on the observed antihypertensive response.
Another explanation could lie within the kidney. Multi-
ple transporters function as regulators of acid–base bal-
ance, blood volume, and blood pressure, and defects or
disturbances in these transporters, either due to kidney
disease or because of genetic mutations, could con-
tribute to hypertension.22,23 Publications on the genetics
of hypertension in cats are currently lacking.
None of the other clinical and biochemical variables
predicted the required dose of amlodipine. Plasma crea-
tinine concentration was not significantly different
between the groups included in this study and did not
function as a predictor of antihypertensive response.
Most human hypertensive subjects are diagnosed with
essential hypertension, in contrast to cats, most of
which have kidney disease. Having CKD significantly
increases the risk for a cat to become hypertensive11
and the majority of cats included in the current study
(45/59 cats in group A and 26/41 cats in group B) were
diagnosed with CKD. The other cats were considered
to have idiopathic hypertension, as no other underlying
disease was diagnosed. It is, however, possible that a
proportion of these cats suffered from nonazotemic
CKD. No correlation was found between creatinine and
SBP response, contrary to what has been described in
humans.2 This could possibly be explained by the fact
that the cat population is more homogenous in renal
function than the human population, as most cats with
hypertension suffer from CKD,1 whereas in humans,
CKD accounts for only a minority of the hypertension
cases.2 An alternative explanation could be that habit-
ual drinking and dialysis contributes to fluid loading in
humans, whereas CKD in the cat is associated with
dehydration or hypovolemia, which tends to lead to
reduced blood pressure.24
Cats that ultimately needed a greater dose to ade-
quately control their blood pressure had a significantly
higher blood pressure at presentation, but both groups
had comparable SBP when normotensive control was
Table 2. Univariable linear regression models investi-
gating the association between biochemical and clinical
variables and the absolute decrease in SBP.
Estimate  SE P-value n
Plasma amlodipine concentration 15.7  2.6 <.001 100
Dose (mg/kg) 94.8  18.9 <.001 99
Treatment time (days) 0.04  0.06 .499 100
Weight (kg) 2.31  2.02 .257 99
Heart rate (bpm) 0.02  0.08 .841 98
Hypertensive SBP (mmHg) 0.89  0.06 <.001 100
PCV (L/L) 0.26  0.35 .459 99
log(Creatinine (mg/dL) 1.4  6.0 .819 99
Urea (mmol/L) 0.14  0.35 .683 99
log(Potassium [mEq/L]) 34.8  16.3 <.05 99
Sodium (mEq/L) 0.70  0.77 .366 99
Chloride (mEq/L) 0.77  0.73 .293 99
log(Total Calcium [mg/dL]) 8.4  30.0 .779 99
Cholesterol (mg/dL) 0.008  0.04 .830 99
PCV, packed cell volume; SBP, systolic blood pressure.
Variables depicted in bold were significantly associated with the
absolute decrease in SBP at the 10% level and were included in
the multivariable linear regression model. The plasma amlodipine
concentration and hypertensive SBP remained significantly associ-
ated with the decrease in SBP on amlodipine treatment.
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achieved. As there was an independent correlation
between the absolute decrease in SBP and plasma
amlodipine concentration, it could be suggested that
cats with a greater SBP at initial presentation need to
be started on a higher dose of amlodipine immediately.
Based on the association between SBP at hypertensive
visit and the required dose, the proposed starting dose
for cats with a SBP ≥200 mmHg would be 1.25 mg
amlodipine daily. Case reports exist in the literature of
severe hypotension following an amlodipine overdose in
humans,25 and therefore, the recommendation is to
monitor the patient’s blood pressure 1 week after start-
ing the medication. The relationship between plasma
amlodipine concentration and absolute reduction in
SBP has not been examined in the cat and studies inves-
tigating the safety margin of amlodipine and pharma-
cokinetic and pharmacodynamic (PK/PD) studies need
to be performed in order to confirm this.
This study has a number of limitations. Firstly, cats
were chosen for this study based on historically
acquired data, which means that potentially important
clinical information, such as time of last dosing, was
missing for most subjects, precluding it from inclusion
in the statistical analyses. However, plasma concentra-
tions are expected to have already reached steady state
in the cats included in this study, which might mean
that time of last dosing was less important information.
Secondly, cats only had blood samples taken when
there was a clinical indication to do so. This means that
we cannot be certain whether the cats that needed a
dose increase from 0.625 to 1.25 mg/day were truly
receiving the medication at the visit that the dose was
increased. However, cats that were on a dose of
1.25 mg/day also had a blood amlodipine concentration
that was twice as high as the concentration of cats that
were on 0.625 mg, and the cats that needed 1.25 mg to
adequately control their blood pressure also had signifi-
cantly higher blood pressure at presentation. This
makes it less likely that compliance was an issue in the
less-responsive cats. The fact that there is a direct rela-
tionship between oral dose and plasma concentration,
with a doubling of the dose of amlodipine resulting in a
doubling of the plasma concentration, indicates that dif-
ferences in oral bioavailability do not seem to play a
role in the relative resistance of certain cats.
In conclusion, cats that need a higher dose of amlodip-
ine to reach a target SBP of <160 mmHg have higher
SBP at diagnosis of their hypertension, and lower plasma
potassium concentration. Clinical response, measured by
the decrease in SBP, is correlated with the plasma
amlodipine concentration and the SBP at hypertensive
visit. Cats with a higher blood pressure at presentation
could benefit from a higher starting dose of amlodipine.
Based on the data in this study, doses of 1.25 mg of
amlodipine might be considered for therapy of systemic
hypertension in cats with SBP ≥200 mmHg at diagnosis.
Future work is necessary to investigate whether there is a
difference in pathophysiological mechanisms causing the
hypertension in the cats that respond well and the cats
that respond less well.
Footnotes
a Parks Electronic Doppler Model 811B; Perimed UK, Bury St
Edmunds, UK
b Mistral 3000, Sanyo-Gallenkamp, Leicestershire, UK
c IDEXX Laboratories, Wetherby, Yorkshire, UK
d IstinTM (Pfizer Ltd. Sandwich, Kent, UK)
e R Core Team (2014). R: A language and environment for statis-
tical computing. R Foundation for Statistical Computing,
Vienna, Austria
f GraphPad Prism version 6.00 for Windows, GraphPad Software,
San Diego, CA
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